22. Y. Kawashima et al., Powder Technol. 130 (1), 283–289 (2003).
23. A.P. Pawar et al., AAPS PharmSciTech.
5 (3), Article 44 (2004).
24. S. Bhadra et al., Pharm. Technol.
28 (2), 66–76 (2004).
25. M. Maghsoodi et al., Drug Dev. Ind. Pharm. 33 (11), 1216–1224 (2007).
26. J. Katta and A.C. Rasmuson, Int. J. Pharm. 348 (1–2), 61–69 (2008).
27. T. Lee, C.S. Kuo, and Y.H. Chen, Pharm. Technol.
30 (10), 72–92 (2006).
28. T. Lee, Y. H. Chen and C.W. Zhang, Pharm. Technol.
31 (6), 72–87 (2007).
29. T. Lee and M.S. Lin, Cryst. Growth and Design
7 (9), 1803–1810 (2007).
30. T. Lee et al., Pharm. Technol.
33 (6), 54-61 (2009).
31. J. Alsenz and M. Kansy, Adv. Drug Deliv. Rev.
59 (7), 546–567 (2007).
32. L.E. McMahon et al., J. Pharm. Sci. 85 (10), 1064–1069 (1996).
33. A.L. Grzesiak et al., J. Pharm. Sci.
92 (11), 2260–2271 (2003).
34. N. Rodríguez-Hornedo and D. Murphy, J. Pharm. Sci.
93 (2), 449–460 (2004).
35. F. Tian et al., J. Pharm. Sci.
96 (3), 584–594 (2007).
36. B. Hegedüs and S. Görög, J. Pharm. Biomed. Analysis
3 (4), 303–313 (1985).
37. S. Sudo, K. Sato, and Y. Harano, J. Chem. Eng. Japan
24 (2), 237–242 (1991).
38. A. M. Tudor et al., Spectrochimica Acta, 47A (9–10), 1389–1393 (1991).
39. A. Bauer-Brandl, Intl. J. Pharm.
140 (2), 195–206 (1996).
40. W.A. Bueno and E.G. Sobrinho, Spectrochimica Acta
51A (2), 287–292 (1995).
41. M.D. Tuladhar, J.E. Carless, and M.P. Summers, J. Pharm. Pharmacol. 35 (4), 208–214 (1983).
42. T. Hosokawa et al., Cryst. Eng. Comm. 6 (44), 243–249 (2004).
Note
The results and related discussion will be included in Part II of this article, which appear in the April 2010 issue of Pharmceutical Technology.
Note
For a detailed review of approaches in initial solvent screening, see Part I and Part II of the article, "Initial Solvent
Screening of Carbamazepine, Cimetidine, and Phenylbutazone," which respectively appeared in the May and April 2009 issues
of Pharmaceutical Technology.
|
